Genvor Inc

$ Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224018844 Filed on May 13, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$8.920K	$1.510K
YoY Change	490.73%
Cash & Equivalents	$8.923K	$1.513K
Short-Term Investments
Other Short-Term Assets	$9.980K	$15.40K
YoY Change	-35.18%
Inventory
Prepaid Expenses	$9.975K
Receivables
Other Receivables
Total Short-Term Assets	$18.90K	$16.91K
YoY Change	11.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.82K	$16.65K
YoY Change	-11.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$14.82K	$16.65K
YoY Change	-11.0%
TOTAL ASSETS
Total Short-Term Assets	$18.90K	$16.91K
Total Long-Term Assets	$14.82K	$16.65K
Total Assets	$33.72K	$33.56K
YoY Change	0.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$181.0K	$302.3K
YoY Change	-40.11%	5396.36%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$48.75K	$48.75K
YoY Change	0.0%
Long-Term Debt Due	$867.0K	$1.162M
YoY Change	-25.39%
Total Short-Term Liabilities	$1.135M	$1.763M
YoY Change	-35.65%	4012.92%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$149.4K
YoY Change	-100.0%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$149.4K
YoY Change	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.135M	$1.763M
Total Long-Term Liabilities	$0.00	$149.4K
Total Liabilities	$1.135M	$1.913M
YoY Change	-40.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$19.84M	-$16.69M
YoY Change	18.9%	20828.96%
Common Stock	$20.10K	$18.42K
YoY Change	9.08%	-7.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$300.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.101M	-$1.879M
YoY Change
Total Liabilities & Shareholders Equity	$33.72K	$33.56K
YoY Change	0.46%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Entity Central Index Key EntityCentralIndexKey	0001792941
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Revenues Revenues		usd
CY2023Q1	us-gaap	Revenues Revenues		usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
CY2023Q1	us-gaap	Marketing Expense MarketingExpense		usd
	us-gaap	Marketing Expense MarketingExpense		usd
CY2023Q1	GNVR	Investor And Public Relations InvestorAndPublicRelations		usd
	GNVR	Investor And Public Relations InvestorAndPublicRelations		usd
CY2024Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization		usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization		usd
CY2023Q1	GNVR	Gain On Settlement Of Liabilities GainOnSettlementOfLiabilities		usd
	GNVR	Gain On Settlement Of Liabilities GainOnSettlementOfLiabilities		usd
CY2022Q4	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2023Q4	GNVR	Stock Issued During Period Value Issued Erroneously Omitted From Prior Year StockIssuedDuringPeriodValueIssuedErroneouslyOmittedFromPriorYear		usd
CY2023Q4	GNVR	Stock Issued During Period Value Issued For Double Issuance Of Common Stock StockIssuedDuringPeriodValueIssuedForDoubleIssuanceOfCommonStock		usd
CY2024Q1	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	GNVR	Gain On Settlement Of Liabilities GainOnSettlementOfLiabilities		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets		usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties		usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	GNVR	Conversion Of Note Payable Into Common Stock ConversionOfNotePayableIntoCommonStock		usd
	GNVR	Conversion Of Notes Payable Into Warrants ConversionOfNotesPayableIntoWarrants		usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-56589
	dei	Entity Registrant Name EntityRegistrantName	GENVOR INCORPORATED
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-2054746
	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 S. Elliott Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 538
	dei	Entity Address City Or Town EntityAddressCityOrTown	Chapel Hill
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NC
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	27514
	dei	City Area Code CityAreaCode	(984)
	dei	Local Phone Number LocalPhoneNumber	261-7338
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20204608	shares
CY2024Q1	us-gaap	Cash Cash	8923	usd
CY2023Q3	us-gaap	Cash Cash	44354	usd
CY2024Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	9975	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	21975	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	18898	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	66329	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14818	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15734	usd
CY2024Q1	us-gaap	Assets Assets	33716	usd
CY2023Q3	us-gaap	Assets Assets	82063	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	867000	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1319500	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	181044	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	388809	usd
CY2024Q1	us-gaap	Loans Payable Current LoansPayableCurrent	48750	usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent	48750	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1134763	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1787059	usd
CY2024Q1	us-gaap	Liabilities Liabilities	1134763	usd
CY2023Q3	us-gaap	Liabilities Liabilities	1787059	usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20094608	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20094608	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19061936	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19061936	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	20095	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	19062	usd
CY2024Q1	us-gaap	Treasury Stock Value TreasuryStockValue	300000	usd
CY2023Q3	us-gaap	Treasury Stock Value TreasuryStockValue	300000	usd
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	19019586	usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	16293188	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19842789	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17719307	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1101047	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1704996	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	33716	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	82063	usd
CY2024Q1	us-gaap	Professional Fees ProfessionalFees	177453	usd
CY2023Q1	us-gaap	Professional Fees ProfessionalFees	58858	usd
	us-gaap	Professional Fees ProfessionalFees	445039	usd
	us-gaap	Professional Fees ProfessionalFees	65662	usd
CY2024Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	69965	usd
CY2023Q1	us-gaap	Labor And Related Expense LaborAndRelatedExpense	37500	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	69965	usd
	us-gaap	Labor And Related Expense LaborAndRelatedExpense	75000	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33110	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33110	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	406250	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1313350	usd
CY2024Q1	us-gaap	Marketing Expense MarketingExpense	8297	usd
	us-gaap	Marketing Expense MarketingExpense	8297	usd
CY2024Q1	GNVR	Investor And Public Relations InvestorAndPublicRelations	38750	usd
	GNVR	Investor And Public Relations InvestorAndPublicRelations	74750	usd
CY2024Q1	GNVR	Other General And Administrative Expenses OtherGeneralAndAdministrativeExpenses	13575	usd
CY2023Q1	GNVR	Other General And Administrative Expenses OtherGeneralAndAdministrativeExpenses	58924	usd
	GNVR	Other General And Administrative Expenses OtherGeneralAndAdministrativeExpenses	107965	usd
	GNVR	Other General And Administrative Expenses OtherGeneralAndAdministrativeExpenses	128282	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	747400	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	155282	usd
	us-gaap	Operating Expenses OperatingExpenses	2052476	usd
	us-gaap	Operating Expenses OperatingExpenses	268944	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-747400	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-155282	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2052476	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-268944	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	481	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	5819	usd
	us-gaap	Interest Expense InterestExpense	16832	usd
	us-gaap	Interest Expense InterestExpense	11665	usd
CY2024Q1	GNVR	Penalties Penalties	-30000	usd
CY2023Q1	GNVR	Penalties Penalties	-30000	usd
	GNVR	Penalties Penalties	-60000	usd
	GNVR	Penalties Penalties	-60000	usd
CY2023Q1	us-gaap	Adjustment For Amortization AdjustmentForAmortization	30111	usd
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	60222	usd
CY2024Q1	GNVR	Gain On Settlement Of Liabilities GainOnSettlementOfLiabilities	5826	usd
	GNVR	Gain On Settlement Of Liabilities GainOnSettlementOfLiabilities	5826	usd
CY2024Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-24655	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-65930	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-71006	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-131887	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-772055	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-221212	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123482	usd
	us-gaap	Net Income Loss NetIncomeLoss	-400831	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.01
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.01
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19669477	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19669477	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18381710	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18381710	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	19596756	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	19596756	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	20449202	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	20449202	shares
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-1394444	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	150000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-179619	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1424063	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	12500	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-221212	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-1632775	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1704996	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	578600	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	907100	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	329418	usd
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	48063	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1351427	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1193242	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1193242	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	306250	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	210000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	248000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	100000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-772055	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1101047	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-1101047	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2123482	usd
	us-gaap	Net Income Loss NetIncomeLoss	-400831	usd
	us-gaap	Depreciation Depreciation	916	usd
	us-gaap	Depreciation Depreciation	916	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1313350	usd
	GNVR	Late Fee Capitalized Into Notes Payable LateFeeCapitalizedIntoNotesPayable	60000	usd
	GNVR	Late Fee Capitalized Into Notes Payable LateFeeCapitalizedIntoNotesPayable	60000	usd
	GNVR	Gain On Settlement Of Liabilities GainOnSettlementOfLiabilities	5826	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	60222	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-12000	usd
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	13397	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-126958	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	32117	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	7969	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-246400	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-862031	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-507373	usd
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	50000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	826600	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	162500	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	826600	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	212500	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-35431	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-294873	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	44354	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	296386	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8923	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1513	usd
	GNVR	Conversion Of Note Payable Into Common Stock ConversionOfNotePayableIntoCommonStock	258063	usd
	GNVR	Conversion Of Notes Payable Into Warrants ConversionOfNotesPayableIntoWarrants	329418	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19842789	usd
	us-gaap	Profit Loss ProfitLoss	2123482	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-862031	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84D_eus-gaap--UseOfEstimates_ztenHa5Sz8R5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zupVngReEcIg">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	33110	usd
	GNVR	Late Fees LateFees	60000	usd
	GNVR	Late Fees LateFees	60000	usd
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	Dilutive Securities DilutiveSecurities	0	usd
	us-gaap	Dilutive Securities DilutiveSecurities	665000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	867000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	16832	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	11665	usd
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q2	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	569	shares
CY2022Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.50
CY2022Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	285	usd
CY2022Q2	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	18144112	shares
CY2022Q2	GNVR	Number Of Shares Retained NumberOfSharesRetained	1855888	shares
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	25000	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	25000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1250	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1250	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	6250	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6250	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	1429	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1429	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	13393	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	13393	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	25000	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	25000	usd
CY2023Q2	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	25000	shares
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	12500	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	29665	shares
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	14833	usd
CY2023Q4	GNVR	Stock Issued During Period Shares Issued For Prior Year StockIssuedDuringPeriodSharesIssuedForPriorYear	50000	shares
CY2023Q4	GNVR	Stock Issued During Period Value Issued For Prior Year StockIssuedDuringPeriodValueIssuedForPriorYear	12500	usd
CY2023Q4	GNVR	Stock Issued During Period Shares Issued For Double Issuance Of Common Stock Shares StockIssuedDuringPeriodSharesIssuedForDoubleIssuanceOfCommonStockShares	60000	shares
CY2023Q4	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	40000	shares
CY2023Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	32500	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Conversion Of Convertible Securities StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	210000	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	200000	usd
CY2024Q1	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	10000	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	450000	shares
CY2023Q3	us-gaap	Assets Held In Trust AssetsHeldInTrust	19705	usd
CY2024Q1	us-gaap	Assets Held In Trust AssetsHeldInTrust	19705	usd
CY2022Q3	us-gaap	Assets Held In Trust AssetsHeldInTrust	19705	usd
	us-gaap	Investment Company Excess Expense Reimbursable InvestmentCompanyExcessExpenseReimbursable	5409	usd
CY2024Q1	us-gaap	Compensated Absences Liability CompensatedAbsencesLiability	28714	usd

Files In Submission

Name	View Source	Status
0001493152-24-018844-index-headers.html	Edgar Link	pending
0001493152-24-018844-index.html	Edgar Link	pending
0001493152-24-018844.txt	Edgar Link	pending
0001493152-24-018844-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
form10-q_002.jpg	Edgar Link	pending
form10-q_003.jpg	Edgar Link	pending
form10-q_004.jpg	Edgar Link	pending
form10-q_005.jpg	Edgar Link	pending
form10-q_006.jpg	Edgar Link	pending
form10-q_007.jpg	Edgar Link	pending
gnvr-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
gnvr-20240331_cal.xml	Edgar Link	unprocessable
gnvr-20240331_def.xml	Edgar Link	unprocessable
gnvr-20240331_lab.xml	Edgar Link	unprocessable
gnvr-20240331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

Genvor Inc

2024 Q2 Form 10-Q Financial Statement

#000149315224018844 Filed on May 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission